Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial
Open Access
- 11 September 2024
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-13
Abstract
In the phase 3 Coronavirus Efficacy (COVE) trial (NCT04470427), post-dose two Ancestral Spike-specific binding (bAb) and neutralizing (nAb) antibodies were shown to be correlates of risk (CoR) and of protection against Ancestral-lineage COVID-19 in SARS-CoV-2 naive participants. In the SARS-CoV-2 Omicron era, Omicron subvariants with varying degrees of immune escape now dominate, seropositivity rates are high, and booster doses are administered, raising questions on whether and how these developments affect the bAb and nAb correlates. To address these questions, we assess post-boost BA.1 Spike-specific bAbs and nAbs as CoRs and as correlates of booster efficacy in COVE. For naive individuals, bAbs and nAbs inversely correlate with Omicron COVID-19: hazard ratios (HR) per 10-fold marker increase (95% confidence interval) are 0.16 (0.03, 0.79) and 0.31 (0.10, 0.96), respectively. In non-naive individuals the analogous results are similar: 0.15 (0.04, 0.63) and 0.28 (0.07, 1.08). For naive individuals, three vs two-dose booster efficacy correlates with predicted nAb titer at exposure, with estimates -8% (-126%, 48%), 50% (25%, 67%), and 74% (49%, 87%), at 56, 251, and 891 Arbitrary Units/ml. These results support the continued use of antibody as a surrogate endpoint.Keywords
All Related Versions
This publication has 34 references indexed in Scilit:
- Neutralization Profile after Recovery from SARS-CoV-2 Omicron InfectionNew England Journal of Medicine, 2022
- Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trialNature Medicine, 2022
- SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent PersonsNew England Journal of Medicine, 2022
- Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trialScience, 2022
- Activity of convalescent and vaccine serum against SARS-CoV-2 OmicronNature, 2021
- Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralizationNature, 2021
- Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded PhaseNew England Journal of Medicine, 2021
- mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infectionScience, 2021
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineNew England Journal of Medicine, 2021
- Super LearnerStatistical Applications in Genetics and Molecular Biology, 2007